Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Advanced Micro Devices, Inc.'s valuation is far too high in the near term and not a buy now. Click here to read an analysis ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

A rally in big tech drove stocks toward fresh all-time highs on the eve of a key jobs report that’s forecast to show moderation in hiring, and help make the case for the Federal Reserve to cut ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of countries.

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.